ISRCTN14861313已完成未知
PRO-REHAB - The development and pilot trial of two programmes of rehabilitation for cancer patients: a pilot randomised controlled trial
niversity of Warwick0 个研究点目标入组 170 人开始时间: 2015年1月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. With cancer (breast, colorectal, head and neck, lung and prostate) of any stage, will be invited to participate along with their carers
- •2. Who have completed the initial phase of intensive intervention (surgery, chemotherapy and/or radiotherapy)
- •3. Are able to read written and comprehend spoken English
- •4. Are aged 18 years and over
- •5. Are able and willing to give informed consent; Target Gender: Male & Female ; Lower Age Limit 18 no age limit or unit specified
排除标准
- •1. Aged less than 18 years
- •2. With a history of severe psychiatric disorder
研究者
相似试验
尚未招募
Unknown
Phase II trial to evaluate the feasibility of preoperative weight loss program for obese patients with gastric cancerGastric cancerJPRN-UMIN000052546Gastric Surgery, Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research30
进行中（未招募）
不适用
Phase II clinical study for the therapy of cystic fibrosis patients with aspecific mutatioCystic fibrosis patients with F508del-CFTR in homozygous or compound heterozygous with Class I or II mutationsEUCTR2013-001258-82-ITEuropean Institute for Cystic Fibrosis Research (IERFC)
已完成
不适用
REBIRTH - Pilot study in preperation for a population based intervention study for moleculare translationale research in the area of primary preventiohealthy subjectsDRKS00013885Rebirth Exzellenzcluster, MHH89
进行中（未招募）
2 期
A Multi Centre, Pilot Phase II Trial Assessing The Efficacy And Safety Of Bevacizumab + Gemcitabine + Carboplatin As First Line Treatment For Patients Diagnosed With Triple Negative Metastatic Breast Cancer.CTRI/2010/091/001135Roche Products India Pvt Ltd44
进行中（未招募）
1 期
A trial examining the effects of alteplase in patients with severe respiratory failure.EUCTR2010-024377-40-ATMedizinische Universität Wien, UniKlinik für Klinische Pharmakologie